The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Survivin: a unique target for tumor therapy
Open accessAbstract
Survivin is the smallest member of the Inhibitor of apoptosis (IAP) family of proteins, involved in inhibition of apoptosis and regulation of cell cycle. These functional attributes make Survivin a unique protein exhibiting divergent functions i.e. regulating cell proliferation and cell death. Expression pattern of Survivin is also distinctive; it is prominently expressed during embryonal development, absent in most normal, terminally differentiated tissues but upregulated in a variety of human cancers. Expression of Survivin in tumours correlates with not only inhibition of apoptosis and a decreased rate of cell death, but also resistance to chemotherapy and aggressiveness of tumours. Therefore, Survivin is an important target for cancer vaccines and therapeutics. Survivin has also been found to be prominently expressed on both human and embryonic stem cells and many somatic stem cell types indicating its yet unexplored role in stem cell generation and maintenance. Overall, Survivin emerges as a molecule with much wider role in cellular homeostasis. This review will discuss various aspects of Survivin biology and its role in regulation of apoptosis, cell division, chemo-resistance and tumour progression. Various molecular and immunotherapeutic approaches targeting Survivin will also be discussed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838
IAP proteins: blocking the road to death's door
Salvesen, G. S., & Duckett, C. S. (2002) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm830 · Cited by 1,756
Type I interferon is selectively required by dendritic cells for immune rejection of tumors
Diamond, M. S., Kinder, M., Matsushita, H., Mashayekhi, M., Dunn, G. P., Archambault, J. M., Lee, H., Arthur, C. D., White, J. M., Kalinke, U., et al. (2011) · Journal of Experimental Medicine · doi:10.1084/jem.20101158 · Cited by 1,081
Human inhibitor of apoptosis proteins: why XIAP is the black sheep of the family
Eckelman, B. P., Salvesen, G. S., & Scott, F. L. (2006) · The EMBO Reports · doi:10.1038/sj.embor.7400795 · Cited by 813
Widenmeyer, M., Griesemann, H., Stevanović, S., Feyerabend, S., Klein, R., Attig, S., Hennenlotter, J., Wernet, D., Kuprash, D. V., Sazykin, A. Y., et al. (2012) · International Journal of Cancer · doi:10.1002/ijc.26365 · Cited by 70
Cited by
Musa, J., Aynaud, M.-M., Mirabeau, O., Delattre, O., & Grünewald, T. G. (2017) · Cell Death & Disease · doi:10.1038/cddis.2017.244 · Cited by 322
Evolution of Cancer Vaccines—Challenges, Achievements, and Future Directions
Tay, B. Q., Wright, Q., Ladwa, R., Perry, C., Leggatt, G., Simpson, F., Wells, J. W., Panizza, B. J., Frazer, I. H., & Cruz, J. L. G. (2021) · Vaccines · doi:10.3390/vaccines9050535 · Cited by 76
Exosome-mediated delivery of siRNA molecules in cancer therapy: triumphs and challenges
Ubanako, P., Mirza, S., Ruff, P., & Penny, C. (2024) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2024.1447953 · Cited by 68
Fahey, J. M., Stancill, J. S., Smith, B. C., & Girotti, A. W. (2018) · Journal of Biological Chemistry · doi:10.1074/jbc.ra117.000443 · Cited by 59
Differentiation Therapy Targeting the β-Catenin/CBP Interaction in Pancreatic Cancer
Manegold, P., Lai, K., Wu, Y., Teo, J.-L., Lenz, H.-J., Genyk, Y., Pandol, S., Wu, K., Lin, D., Chen, Y., et al. (2018) · Cancers · doi:10.3390/cancers10040095 · Cited by 51
Metadata
- Authors
- Garg, H., Suri, P., Gupta, J. C., Talwar, G. P., & Dubey, S.
- Venue
- Cancer Cell International
- Published
- 2016-06-23
- Volume
- 16
- Issue
- 1
- Pages
- 49-49
- ISSN
- 1475-2867 (ISSN-L)
- OpenAlex
- W2462022051
- Cited by
- 437
- References
- 5
- FWCI
- 20.31
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Survivin: a unique target for tumor therapy. https://app.cochat.ai/papers/10.1186/s12935-016-0326-1
- The paper
- Garg, H., Suri, P., Gupta, J. C., Talwar, G. P., & Dubey, S. (2016). Survivin: a unique target for tumor therapy. Cancer Cell International. https://doi.org/10.1186/s12935-016-0326-1
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
